MX2020002652A - Esteroides neuroactivos y su método de uso. - Google Patents

Esteroides neuroactivos y su método de uso.

Info

Publication number
MX2020002652A
MX2020002652A MX2020002652A MX2020002652A MX2020002652A MX 2020002652 A MX2020002652 A MX 2020002652A MX 2020002652 A MX2020002652 A MX 2020002652A MX 2020002652 A MX2020002652 A MX 2020002652A MX 2020002652 A MX2020002652 A MX 2020002652A
Authority
MX
Mexico
Prior art keywords
methods
pharmaceutically acceptable
compound
neuroactive steroids
related disorders
Prior art date
Application number
MX2020002652A
Other languages
English (en)
Inventor
Stephen Jay Kanes
Ethan Hoffmann
George Nomikos
Handan Gunduz-Bruce
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2020002652A publication Critical patent/MX2020002652A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere al Compuesto 1(VER FORMULA) (Compuesto 1) sales farmacéuticamente aceptables, o composiciones farmacéuticamente aceptables del mismo, para el tratamiento de trastornos relacionados con el SNC, por ej. temblor, por ej. temblor esencial; depresión; y trastorno de la ansiedad, y métodos para mejorar la efectividad de la administración del Compuesto 1 para tratar dichos trastornos relacionados con el SNC. La invención también se refiere a métodos para incrementar la biodisponibilidad de un Compuesto 1 o sales farmacéuticamente aceptables, o composiciones farmacéuticamente aceptables del mismo.
MX2020002652A 2017-09-07 2018-09-07 Esteroides neuroactivos y su método de uso. MX2020002652A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555404P 2017-09-07 2017-09-07
US201762595998P 2017-12-07 2017-12-07
PCT/US2018/050012 WO2019051264A1 (en) 2017-09-07 2018-09-07 NEUROACTIVE STEROIDS AND METHODS OF USE

Publications (1)

Publication Number Publication Date
MX2020002652A true MX2020002652A (es) 2020-09-25

Family

ID=63794613

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020002652A MX2020002652A (es) 2017-09-07 2018-09-07 Esteroides neuroactivos y su método de uso.
MX2023009611A MX2023009611A (es) 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso.
MX2023009610A MX2023009610A (es) 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2023009611A MX2023009611A (es) 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso.
MX2023009610A MX2023009610A (es) 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso.

Country Status (11)

Country Link
US (2) US20200281943A1 (es)
EP (1) EP3678670A1 (es)
JP (3) JP2020533310A (es)
CN (2) CN117771252A (es)
AU (3) AU2018327357B2 (es)
CA (1) CA3075038A1 (es)
IL (2) IL303250A (es)
MX (3) MX2020002652A (es)
SG (1) SG11202002085YA (es)
TW (2) TW202342058A (es)
WO (1) WO2019051264A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
RU2019126333A (ru) 2013-04-17 2019-10-08 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
CN113527400B (zh) 2013-04-17 2024-06-28 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AU2014308621C1 (en) 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
MX2021004492A (es) 2014-10-16 2022-12-05 Sage Therapeutics Inc Composiciones para el tratamiento de trastornos del snc.
SMT202000414T1 (it) 2014-10-16 2020-09-10 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
ME03749B (me) 2014-11-27 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
CN115974956A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
EP3681510A1 (en) * 2017-09-14 2020-07-22 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
CN117959309A (zh) * 2018-06-12 2024-05-03 萨奇治疗股份有限公司 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
US20220220149A1 (en) * 2019-05-28 2022-07-14 Teva Czech Industries S.R.O Solid state forms of sage-217 and processes for preparation thereof
CN114206900A (zh) * 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物
TWI896547B (zh) * 2019-06-27 2025-09-11 美商賽吉醫療公司 用於治療cns病症之組合物及方法
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
AU2020395246A1 (en) * 2019-12-05 2022-06-16 Sage Therapeutics, Inc. A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof
PE20221911A1 (es) 2020-03-25 2022-12-23 Sage Therapeutics Inc Uso de agentes para el tratamiento de condiciones respiratorias
BR112023000990A2 (pt) * 2020-07-20 2023-03-28 Sage Therapeutics Inc Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas
US20230372365A1 (en) * 2020-10-01 2023-11-23 Andrew D. Levin Methods of treating fibromyalgia with neuroactive steroids
WO2022072621A1 (en) * 2020-10-01 2022-04-07 Eliem Therapeutics (UK) Ltd Method of treating gaba mediated disorders
US20240245711A1 (en) * 2021-03-17 2024-07-25 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
CA3217866A1 (en) * 2021-04-29 2022-11-03 Sage Therapeutics, Inc. Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
TW202308654A (zh) * 2021-04-29 2023-03-01 美商賽吉醫療公司 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2168585T1 (sl) * 2005-06-09 2012-04-30 Euro Celtique Sa Farmacevtski sestavki nevroaktivnega steroida in njihove uporabe
CA2698172C (en) * 2007-06-15 2014-02-18 Cook, Kevin M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
CN113527400B (zh) * 2013-04-17 2024-06-28 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
RU2766155C2 (ru) * 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
CN115974956A (zh) * 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体

Also Published As

Publication number Publication date
AU2018327357B2 (en) 2024-08-22
JP2020533310A (ja) 2020-11-19
EP3678670A1 (en) 2020-07-15
TW202342058A (zh) 2023-11-01
JP2024133114A (ja) 2024-10-01
MX2023009611A (es) 2023-08-24
CN117771252A (zh) 2024-03-29
US20230310459A1 (en) 2023-10-05
SG11202002085YA (en) 2020-04-29
WO2019051264A1 (en) 2019-03-14
TW201919641A (zh) 2019-06-01
AU2024227546A1 (en) 2024-11-14
CA3075038A1 (en) 2019-03-14
JP2023033543A (ja) 2023-03-10
IL273099A (en) 2020-04-30
US20200281943A1 (en) 2020-09-10
AU2024205519A1 (en) 2024-08-22
AU2018327357A1 (en) 2020-03-26
CN111491637A (zh) 2020-08-04
MX2023009610A (es) 2023-08-24
IL303250A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
MX2023009611A (es) Esteroides neuroactivos, y su metodo de uso.
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
JOP20230235A1 (ar) عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون
MX2021004492A (es) Composiciones para el tratamiento de trastornos del snc.
MX2020006599A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
JO3530B1 (ar) مركبات بيريدازين 1،4-ثنائية الإرتباط ونظائرها وطرق معالجة نقص smn وحالاته المرضية.
MX2019008626A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
MX2017011951A (es) Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX2024011494A (es) Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para su uso en el tratamiento de trastornos del snc.
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MX2024014845A (es) Esteroides neuroactivos no saturados 9(11) y sus metodos de uso
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
SG10201907289VA (en) Monomethylfumarate prodrug compositions
PH12021550671A1 (en) Prodrugs of cgrp antagonists
PH12020550993A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
MY189372A (en) Indole derivatives
JOP20180057A1 (ar) مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
HK1242201A1 (en) Compositions and methods for treating cns disorders